GH Research PLC (GHRS) Form 6-K — Jun 4, 2026
GH Research PLC announced the publication of its Phase 2a trial results for inhaled mebufotenin (GH001) in postpartum depression, showing a mean MADRS reduction of -35.4 points and 100% remission rate among the 10 enrolled patients. The study, published in The Journal of Clinical Psychiatry, demonstrated rapid onset of action with remission achieved within two hours of dosing and sustained through Day 8, with no serious adverse events reported.
Key figures
- Remission rate ppd
- 100%
- Madrs reduction ppd
- -35.4
- Madrs reduction trd
- -15.5
- Patients enrolled ppd
- 10
- Maternal functioning increase
- 34.1 points (56%)
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.